

Mumbai, November 3, 2014

## Wockhardt Q2FY15 Net Sales at Rs.1029 crore

	Q2-FY15		Q2-FY14	H1FY15		FY14
	Jul - Sep 2014		Jul - Sep 2013	Apr - Sep 2014		
	Rsc	Gwth Y-O-Y	Rsc	Rsc	Gwth Y-O-Y	
Sales	1,029	-14%	1,197	2,020	-21%	4,830
R&D	110	4%	106	221	8%	403
R&D % to Sales	10.7%		8.9%	10.9%		8.3%
Operating Profit	165	-16%	196	226	-63%	980
Op. Profit Margins %	16.0%		16.4%	11.2%		20%
Profit After Tax	3	-98%	138	23	-95%	841
PAT Margins	0.3%		11.5%	1.1%		17%
EPS	0.3		12.6	2.1	-95%	76.6

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 2<sup>nd</sup> quarter and 1<sup>st</sup> Half results for Financial Year 2015, today.

### Dividend

The Board has approved payment of interim dividend of 400% on equity shares i.e. Rs.20/- per equity share.

**PRESS RELEASE**



**Wockhardt Limited**  
| Wockhardt Towers |  
| Bandra Kurla Complex |  
| Mumbai 400 051 | India |  
| Tel.: +91-22-2653 4444 |  
| www.wockhardt.com

---

## **Quarter ended 30<sup>th</sup> September, 2014**

Consolidated revenue for the quarter was Rs.1029 crore and Profit After Tax was at Rs.3 crore.

The company increased its Research spend significantly and the same is now at 10.7% to sales at Rs.110 crores and including capital expenditure is at 11.1% to sales for the quarter.

Wockhardt filed for 12 patents during the quarter taking the cumulative filings to 2065 and has been granted 16 patents during the quarter taking the cumulative patents granted to 300.

## **1<sup>st</sup> Half ended 30<sup>th</sup> September, 2014**

Consolidated revenue for the 1<sup>st</sup> half was Rs.2020 crore and Profit After Tax was at Rs.23 crore.

Research expenses stood at Rs.221 crores for the 1<sup>st</sup> half representing 10.9% of sales and including capital expenditure is at 11.4% of sales.

Wockhardt filed 13 new product applications with USFDA during the 1<sup>st</sup> Half. Cumulative products pending approval with USFDA stands at 75 as on September 2014. Launched 17 new products in India in Q2FY15. UK received 4 approvals and made 9 filings during the 1<sup>st</sup> half year.

## **Capex**

Capital expenditure of Rs.194 crore was incurred in 1<sup>st</sup> half of FY15.

## **Business Highlights**

The India business recorded a growth of 18.1% in Q2FY15 and grew by 18% in 1<sup>st</sup> half of FY15. Emerging Markets business grew by 4.8% in Q2FY15 and by 7.1% in 1<sup>st</sup> half of FY15.

Wockhardt's International Business contributed 67.4% of the Total Revenues during the quarter.

The UK business declined by 3.8% in Q2FY15 and declined by 2% in H1FY15. The Irish market recorded a growth of 14.5% in Q2FY15 and 13.8% in H1FY15. 1 New Product was launched in Irish market in H1FY15.

Wockhardt's US business declined by 56.3% in Q2FY15 and by 58.6% in 1<sup>st</sup> half of FY15 and contributed 24% of the Global Revenues for Wockhardt in Q2FY15 and 26.6% in 1<sup>st</sup> half of FY15.

**PRESS RELEASE**



**Wockhardt Limited**

| Wockhardt Towers |  
| Bandra Kurla Complex |  
| Mumbai 400 051 | India |  
| Tel.: +91-22-2653 4444 |  
| [www.wockhardt.com](http://www.wockhardt.com)

---

Wockhardt launched 17 new products in Domestic Market in Q2FY15 and 33 new products in H1FY15.

***About Wockhardt :***

Wockhardt is a highly technology intensive global pharmaceutical and biotechnology company. It's multi-disciplinary and innovative R&D programmes globally, are strongly focused on creating Intellectual Properties. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 79% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 850 scientists, of whom 80 are doctorates. In all, Wockhardt has 300 Patents granted worldwide. In biotechnology research, it has built competent 'Concept to Market' capability in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 8,600 people from 21 different nationalities.